Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Type 2 Diabetes Mellitus
Phase PHASE3
Enrollment 270
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of Madalena association in the treatment of type 2 diabetes mellitus.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: MADALENA ASSOCIATION — Madalena association coated tablet.
  • Drug: METFORMIN — Metformin 1000 mg extended-release tablet.
  • Drug: EMPAGLIFLOZIN + LINAGLIPTIN — Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
  • Other: MADALENA ASSOCIATION PLACEBO — Madalena association placebo tablet.
  • Other: METFORMIN PLACEBO — Metformin placebo tablet.
  • Other: EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO — Empagliflozin + linagliptin placebo tablet.

Primary Outcomes

  • Change from baseline in glycated hemoglobin (HbA1c) levels. (120 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-11-18
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 270 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: EMS
Contact Information
Study Contact:
Monalisa FB Oliveira, MD
+551938879851
pesquisa.clinica@ncfarma.com.br
Interventions
  • Drug: MADALENA ASSOCIATION — Madalena association coated tablet.
  • Drug: METFORMIN — Metformin 1000 mg extended-release tablet.
  • Drug: EMPAGLIFLOZIN + LINAGLIPTIN — Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
  • Other: MADALENA ASSOCIATION PLACEBO — Madalena association placebo tablet.
  • Other: METFORMIN PLACEBO — Metformin placebo tablet.
Study Locations (1 sites)
EMS, Hortolândia, São Paulo Brazil
Eligibility Criteria
Inclusion Criteria: * Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * Participants with 18 years of age or greater; * Participants presenting the diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goals of HbA1c with previous dietary, physical exercise guidance and at least 3 months with two anti-hyperglycemic agents (dual therapy); * HbA1c ≥ 7,5% and ≤ 10,5% and fasting blood glucose \> 100 mg/dL at the screening visit; * BMI (body mass index) \> 19 Kg/m2 and ≤ 45 Kg/m2. Exclusion Criteria: * Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants; * History of alcohol abuse or illicit drug use; * Participation in a clinical trial in the year prior to this study; * Pregnancy or risk of pregnancy and lactating patients; * Known hypersensitivity to the formula components used during the clinical trial; * Type 1 diabetes mellitus; * Fasting blood glucose \> 300 mg/dL; * Risk factors for volume depletion; * Impaired renal function and end-stage renal disease; * Participants with current treatment and continued for more than 15 days with systemic steroids at the time of informed consent; * Impaired hepatic function; * Medical history of pancreatic diseases that may suggest insulin deficiency; * Bariatric surgery in the last two years and/ or other gastrointestinal surgeries that can cause chronic malabsorption syndrome; * Condition that, in the investigator's judgment, may favor clinically significant changes in CPK levels; * Medical history of acute coronary syndrome, stroke, unstable congestive heart failure, or respiratory failure within 6 months prior to informed consent; * Current medical history of cancer and/ or cancer treatment in the last 5 years; * Medical history of metabolic acidosis and/or using drugs that may cause lactic acidosis; * Medical history of blood dyscrasia or any other hemolytic disorders; * Participants using sulfonylureas and/or insulin therapy; * Treatment with anti-obesity drugs for less than 2 months or with dose change in the last 2 months.
Conditions Diabetes Mellitus, Type 2
Phase Not Applicable
Enrollment 11
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This observational and monocentric study aims to explore how migrant patients with type 2 diabetes perceive and represent food in the context of their diabetes care. Conducted at the Centre Hospitalier de Saint-Denis, the study investigates the cultural, social, and personal factors that influence dietary habits and how these perceptions affect the management of their condition. The goal is to improve the understanding of patient behaviors and support more culturally adapted care strategies.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Representation of food in the care of diabetes in migrants Description (enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-01
Completion: 2025-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 11 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier de Saint-Denis
Contact Information
Study Contact:
COSSEC
+33142356140
coordination.rechercheclinique@ghtpdfr.fr
Centre Hospitalier (CH) de Saint-Denis
Interventions
N/A
Study Locations (1 sites)
Centre Hospitalier (CH) de Saint-Denis, Saint-Denis, France
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetic for at least 3 months * Arrived in France less than 7 years ago * Adult patient (age 18) * Speaking French or English Exclusion Criteria: * Minor patient (age \< 18 years) * Type 1 diabetes * Does not speak French or English * Patient who has expressed opposition to the use of his data, or his refusal to participate
Conditions Diabetes Mellitus, Type 2, Impaired Gluc...
Phase EARLY_PHASE1
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

Type 2 diabetes mellitus (T2DM) and impaired glucose tolerance (IGT) are growing public health challenges. Early intervention in mild T2DM and IGT is essential to prevent disease progression and severe complications. Traditional Chinese Medicine (TCM) provides a potential therapeutic approach. Sanggua tablets, a TCM formula composed of mulberry leaf, bitter melon, kudzu root, Chinese yam, and cassia seed, embody TCM principles of clearing heat, generating body fluids, tonifying the spleen and stomach, and nourishing the lungs and kidneys. Modern studies show that Sanggua tablets effectively lower blood glucose and improve lipid profiles through components like mulberry polysaccharides and bitter melon saponins. These findings suggest their potential as an alternative or complementary therapy for mild T2DM and IGT. This study will conduct a randomized, double-blind, placebo-controlled, parallel-group clinical trial among patients with IGT and mild T2DM. Participants will receive a 16-week intervention with Sanggua tablets. The primary outcome is glycated hemoglobin (HbA1c), with secondary outcomes such as fasting blood glucose (FBG), fasting insulin (FINS), HOMA-IR, lipid profiles and so on. Safety will be closely monitored. Additionally, fecal samples will be collected for 16S rDNA sequencing to explore the role of gut microbiota in the therapeutic effects of Sanggua tablets. This study aims to provide evidence for the clinical application and development of Sanggua tablets as a novel TCM therapy.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Sanggua tablets — Patients will continue their background medications and receive Sang Gua tablets, twice daily (bid).
  • Drug: Placebo — Patients will continue their background medications and receive placebo, twice daily (bid).

Primary Outcomes

  • Hemoglobin A1c (HbA1c, %) (The percentage of glycated hemoglobin will be measured at baseline (V1) and at the end of the treatment period(Week 16 ,V5).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-05-15
Completion: 2027-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tongji Hospital
Principal Investigators:
  • Gang Yuan, Professor (PRINCIPAL_INVESTIGATOR) - Tongji Hospital
Contact Information
Study Contact:
Gang Yuan, Professor
0086-027-13871523102
gangyuan@tjh.tjmu.edu.cn
Gang Yuan, Chief physician, Professor
+8613871523102
gangyuan@tjh.tjmu.edu.cn
Tongji Hospital
Interventions
  • Drug: Sanggua tablets — Patients will continue their background medications and receive Sang Gua tablets, twice daily (bid).
  • Drug: Placebo — Patients will continue their background medications and receive placebo, twice daily (bid).
Study Locations (1 sites)
Tongji Hospital, Wuhan, Hubei 430030 China
Eligibility Criteria
Inclusion Criteria: * Patients aged 18-70 with impaired glucose tolerance (IGT). * Or patients aged 18-70 diagnosed with type 2 diabetes mellitus (T2DM) deemed by the clinician not requiring pharmacological intervention. * And(or) glycated hemoglobin (HbA1c) levels between 5.7% and 7.5%. * Voluntarily sign an informed consent form before the commencement of trial-related activities, understand the procedures and methods of the trial, and are willing and able to strictly adhere to the clinical trial protocol to complete the study. Exclusion Criteria: * Type 1 diabetes mellitus. * Known allergies to Sang Gua tablets or any of its components. * Use of hypoglycemic drugs within the last three months. * Presence of severe primary or secondary respiratory, cardiovascular, hepatic, or renal diseases, rheumatic connective tissue diseases, or hematological disorders. * Uncontrolled or unstable conditions exacerbated by infections, severe electrolyte imbalances, or other factors. * Patients with primary or secondary kidney diseases, hypertension, heart failure, acidosis, or urinary tract infections causing increased urinary protein, excepted. * Patients with psychiatric disorders. * Pregnant or planning to become pregnant women, or nursing mothers. * Patients requiring long-term steroid therapy. * Patients with poorly controlled hypertension or secondary hypertension. * Patients who have been diagnosed with malignant tumors. * Patients who have participated in other clinical trials within the past three months. * Patients deemed by the investigator as unsuitable for this clinical trial due to potential interference with trial results, impediments to full participation in the study, medical history, disease evidence, abnormal treatments, or laboratory values, or any other condition considered by the investigator to pose potential risks for participation in the study.
Conditions Host and Microbiome, Pregnancy Outcomes,...
Phase Not Applicable
Enrollment 20000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

The long-term goal of the Human Genes and Microbiota in Early Life (HuGME) is to explore the short- and long-term effects of maternal microbiota during pregnancy and the microbiota colonization of their offspring early in life and their interaction with the host on maternal-offspring health consequences in later life in the born in Guangzhou cohort study in China. Identification of the effect of microbiota in early life, as well as environmental factors and microbe-host interaction, will lead to a better understanding of disease pathogenesis and provide a foundation for targeted mechanistic investigation into the consequences of microbial-host crosstalk for long-term health. It also can result in new strategies to predict and prevent diseases in later life.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention — No intervention

Primary Outcomes

  • Numbers of participants with Childhood diseases. Including: (42 days, 6 months, 1, 3, 6, 8-9, 14, and18 years of age)
  • Numbers of participants with maternal diseases. Including: (during pregnancy, 42 days, 6 months, 1, 3, 6, 8-9, 14, and18 years after delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-04-01
Completion: 2038-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangzhou Women and Children's Medical Center
Principal Investigators:
  • Xiu Qiu, PhD (PRINCIPAL_INVESTIGATOR) - Study Principal Investigator Guangzhou Women and Children's Medical Center, China
Contact Information
Study Contact:
Xiu Qiu,, PhD
0086 20 38367160
qxiu0161@163.com
Jianrong He, PhD
0086 20 38367159
jianrong.he@bigcs.org
Xiu Qiu, MD,PhD
86-020-38367160
xiu.qiu@bigcs.org
Guangzhou Women and Children's Medical Center, China
Interventions
  • Other: No intervention — No intervention
Study Locations (1 sites)
Guangzhou Women and Children's Medical Center, China, Guangzhou, China
Eligibility Criteria
Inclusion Criteria: Pregnant women with \< 20 weeks of gestation Pregnant women intended to eventually deliver in Guangzhou Women and Children's medical center Permanent residengts of families intended to remain in Guangzhou with their child for ≥3 years Exclusion Criteria: Refuses to have blood and stool samples stored at Born in Guangzhou cohort study Biobank.
Conditions Prediabetes / Type 2 Diabetes
Phase Not Applicable
Enrollment 150
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study is to evaluate whether the Oral Fat Loading Test (OFLT) determines a different response in terms of the quantity, quality, and kinetics of triglyceride-rich lipoproteins in subjects with T2D, prediabetics, and control subjects, and whether triglyceride-rich lipoproteins and inflammatory cytokines after OFLT are potential early biomarkers of the risk of progression to diabetes and the development of complications in a general practice setting. To address these questions, a hybrid cohort study was designed by identifying three groups of subjects: T2D and prediabetics (exposed and near-exposed) and control subjects (unexposed).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Oral Fat Load Test — After a 12-hour overnight fast, each participant will be given a sugar-free mascarpone cream containing 75 g of fat. Blood samples will be collected before (OFL Time -1 minute) and 1 (OFL Time +1 hour), 2 (OFL Time +2 hours), 3 (OFL Time +3 hours), 4 (OFL Time +4 hours), and 6 (OFL Time +6 hours) hours after the OFL.

Primary Outcomes

  • Triglyceride concentrations after oral fat loading test (From enrollment after two years at the end of the enrollment)
  • Progression from prediabetes to type 2 diabetes (At 36-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-05-14
Completion: 2028-05-14
Eligibility
Age: 50 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Angelina Passaro
Collaborators: University Hospital of Ferrara, S. Anna Hospital, Azienda USL Ferrara, Università degli Studi di Ferrara
Principal Investigators:
  • Angelina Passaro, Degree in Medicine and Surgery (STUDY_CHAIR) - University Hospital of Ferrara "Sant'Anna"
  • Luca Catapano, Degree in Medicine and Surgery (PRINCIPAL_INVESTIGATOR) - Azienda USL Ferrara
  • Angelina Passaro, Degree in Medicine and Surgery (PRINCIPAL_INVESTIGATOR) - University Hospital of Ferrara "Sant'Anna"
Contact Information
Study Contact:
Fabiola Castaldo, Pharmacy
+39 3348330516
fabiola.castaldo@unife.it
Juana M Sanz Molina, Chemistry
szj@unife.it
Fabiola Castaldo, Pharmacy
+39 3348330516
fabiola.castaldo@unife.it
University Hospital "Sant'Anna" of Ferrara
Interventions
  • Diagnostic Test: Oral Fat Load Test — After a 12-hour overnight fast, each participant will be given a sugar-free mascarpone cream containing 75 g of fat. Blood samples will be collected before (OFL Time -1 minute) and 1 (OFL Time +1 hour), 2 (OFL Time +2 hours), 3 (OFL Time +3 hours), 4 (OFL Time +4 hours), and 6 (OFL Time +6 hours) hours after the OFL.
Study Locations (2 sites)
University Hospital "Sant'Anna" of Ferrara, Ferrara, Ferrara 44124 Italy
Nucleo di Cure Primarie di Poggio Renatico - Medicina di Gruppo Poggio Rete Salute Via Salvo D'Acquisto, 1/a, Poggio Renatico, Ferrara 44023 Italy
Eligibility Criteria
Inclusion Criteria: * Males and females aged 50-70 years * BMI between 25-30 kg/m2 * HbA1c ≤7% for T2D * HbA1c ≤6.5% for prediabetes * HbA1c ≤5.7% for controls * Signed Project Information and Informed Consent Form * Signed Data Processing Consent Form Exclusion Criteria: * Lipid-lowering therapy with ezetimibe, fenofibrate, omega-3 fatty acids, or other drugs that can interfere with lipoprotein absorption and metabolism * Chronic Kidney Disease (CKD) with estimated glomerular filtration rate (eGFR) \<60 ml/min and renal impairment (e.g., uACR ≥30 mg/mmol) for 3 months or more * Secondary or syndromic forms of obesity * Patients on insulin therapy * All acute and chronic conditions that, in the opinion of the investigators, may cause bias. * Hospitalization for acute illness or major surgery in the last 6 months * Patients on stable therapy for less than 3 months * Allergy or intolerance to one or more components of the meal used in the protocol * Pregnancy or breastfeeding * Habitual consumption of alcoholic beverages (\>20 g/day for females and \>30 g/day for males) or unwillingness to abstain from alcoholic beverages during the study run-in period * All subjects who do not consent to participate in the study
Conditions Diabete Type 2, Cardiovascular Diseases
Phase PHASE3
Enrollment 10000
Locations 39 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Factorial Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Aspirin — 40 mg non-enteric-coated tablet taken twice daily.
  • Drug: Aspirin Placebo — non-enteric-coated tablet taken twice daily.
  • Drug: Colchicine — 0.5 mg tablet taken once daily
  • Drug: Colchicine Placebo — tablet taken once daily.

Primary Outcomes

  • First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization. (From randomization to occurrence of first event, assessed up to 60 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-12-21
Completion: 2027-12
Eligibility
Age: 55 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Montreal Heart Institute
Contact Information
Study Contact:
Jean-Claude Tardif, MD, FRCPC, FACC, FCAHS
514-376-3330
Jean-Claude.Tardif@icm-mhi.org
Mylène Provencher, PhD
514-461-1300
Mylene.Provencher@mhicc.org
Chrsitopher Reid, MD
+61892667123
christopher.reid@curtin.edu.au
Curtin University
Interventions
  • Drug: Aspirin — 40 mg non-enteric-coated tablet taken twice daily.
  • Drug: Aspirin Placebo — non-enteric-coated tablet taken twice daily.
  • Drug: Colchicine — 0.5 mg tablet taken once daily
  • Drug: Colchicine Placebo — tablet taken once daily.
Study Locations (39 sites)
Curtin University, Bentley, Western Australia 6102 Australia
St. Michael's Hospital, Toronto, Ontario M5B 1W8 Canada
Montreal Heart Institute, Montreal, Quebec Canada
Center for Translational Cardiology and Pragmatic Randomized Trial, Hellerup, 2900 Denmark
Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, 00029 Finland
Maison de Santé du Sud Ruthénois, Luc-la-Primaube, Aveyron 12450 France
MSP Ty santé Vannes Tohannic, Vannes, Brittany Region 56000 France
Maison de Santé Pluriprofessionnelle OLEA, Bezouce, Gard 30320 France
MSPU la Source, Vergèze, Gard 30310 France
MSPU Pins Justaret, Pins-Justaret, Haute-Garonne 31860 France
Eligibility Criteria
Inclusion Criteria: 1. Men and women aged 55 to 80 years 2. Type 2 diabetes treated as per national guidelines 3. No previous history of coronary artery disease-related clinical event 4. And at least one of the following: 1. Duration of diabetes of 5 years or more, 2. HbA1c ≥ 8.0% or more in the last 2 years 3. Active cigarette smoking, 4. High hs-CRP (\> 2.0 mg/L), 5. High coronary calcium score (Agatston score \>100), 6. High TG-levels (≥1.7 mmol/L) despite lipid lowering therapy administered as per guidelines, 7. High LDL-C levels (≥3.5 mmol/L) or high non-HDL-C levels (≥4.2 mmol/L) despite lipid lowering therapy administered as per guidelines 8. High Apo-B (≥1.05 g/L) 9. Reduced HDL-C (\<1.05 mmol/L in men, \<1.3 mmol/L in women), 10. Lp(a) \>50 mg/dL, 11. Peripheral artery disease with stenosis ≥50% or prior revascularization, 12. Cerebrovascular disease with stenosis ≥50% or prior revascularization, 13. Diabetic retinopathy or diabetic neuropathy, 14. Mild or moderate proteinuria (dipstick analysis) or micro-albuminuria 5. Women of childbearing potential must have a negative urine pregnancy test at screening/randomization visit 1 and must agree to use an effective method of birth control throughout the study. Acceptable means of birth control include: oral contraceptives, implantable contraceptives, injectable contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner. Women are considered not of childbearing potential if they either: 1. Have had a hysterectomy or tubal ligation prior to baseline visit or 2. Are postmenopausal defined as no menses for 12 months or a FSH level (if available) in the menopausal range. 6. Patients with the capacity to provide informed consent. Exclusion Criteria: 1. Any prior history of myocardial infarction, angina, coronary revascularization, coronary stenosis \>30%, stroke, transient ischemic attack, or known heart failure 2. Known chronic renal insufficiency defined as an estimated glomerular filtration rate (eGFR), using the MDRD equation, of \< 35 mL/min/1.73m2 3. History of cancer or lymphoproliferative disease within the last 3 years other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix and/or low-grade prostate cancer 4. Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea 5. Peptic ulcer diagnosed within the last 24 months or previous gastro-intestinal bleeding, except for mild hemorrhoidal bleeding more than 5 years ago which is permitted (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo) 6. Pre-existent progressive neuromuscular disease or known CPK level \> 3 times the upper limit of normal as measured within the past 30 days and determined to be non-transient through repeat testing 7. Any of the following known parameters as measured within the past 90 days, and determined to be non-transient through repeat testing: 1. hemoglobin \< 100 g/L 2. 2\. white blood cell count \< 3.0 X 10⁹/L 3. platelet count \<110 X 10⁹/L 4. ALT \> 3 times the upper limit of normal (ULN) 5. total bilirubin \> 2 times ULN (unless due to Gilbert syndrome, which is allowed) 8. History of cirrhosis, chronic active hepatitis or severe hepatic disease 9. Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication 10. History of clinically significant drug or alcohol abuse in the last year 11. Patient is currently using or plans to begin chronic systemic steroid therapy (oral or intravenous) during the study (topical or inhaled steroids are allowed, as well as replacement corticosteroids for adrenal insufficiency) 12. Current chronic treatment with aspirin or another antiplatelet agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo) 13. Chronic treatment with an anticoagulant agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo) 14. Current use of colchicine for other indications (mainly chronic indications consisting of Familial Mediterranean Fever or gout); there is no wash-out period required for patients who have been treated with colchicine and stopped treatment prior to enrolment 15. History of an allergic reaction or significant sensitivity to colchicine 16. History of an allergic reaction or significant sensitivity to aspirin (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo) 17. Chronic treatment with an anti-inflammatory agent (for example, anti-TNF-alpha or nonsteroidal anti-inflammatory drug (NSAID)) 18. Use of an investigational chemical agent less than 30 days or 5 half-lives prior to the screening visit (whichever is longer) 19. Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Conditions Coronary Heart Disease, Anemia, Bronchia...
Phase Not Applicable
Enrollment 16000
Locations 38 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Study is conducted to assess the prevalence and structure of comorbidity among patients undergoing abdominal surgery and produce the stratification of the risk of postoperative complications by identifying independent predictors for its development.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • incidence of postoperative complications (7 days after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-07-01
Completion: 2026-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 16000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Russian Federation of Anesthesiologists and Reanimatologists
Collaborators: Kuban State Medical University
Principal Investigators:
  • Igor Zabolotskikh, MD (PRINCIPAL_INVESTIGATOR) - Russian Federation of Anesthesiologists and Reanimatologists
Contact Information
Study Contact:
Nikita Trembach, PhD
+79528589299
nikitkax@mail.ru
Igor Zabolotskikh, MD
pobeda_zib@mail.ru
Mikhail Kirov, MD
The First City Clinical Hospital. n.a. E. E. Volosevich
Interventions
N/A
Study Locations (38 sites)
The First City Clinical Hospital. n.a. E. E. Volosevich, Arkhangelsk, Russia
Astrakhan State Medical University, Astrakhan, Russia
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Chelyabinsk, Russia
South-Ural State Medical University, Chelyabinsk, Russia
Chita state medical Academy of the Ministry of health of the Russian Federation, Chita, Russia
Kazan State Medical University, Kazan', Russia
Republic Clinical Hospital Ministry of Health care of the Republic of Tatarstan, Kazan', Russia
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, 650002 Russia
Regional clinical hospital №2, Krasnodar, 350012 Russia
Kuban State Medical University, Krasnodar, 350063 Russia
Eligibility Criteria
Inclusion Criteria: * surgical interventions on the abdominal organs, * 1-3 ASA physical status class Exclusion Criteria: * the inability to assess the factors included in the study, * acute massive blood loss, aspiration, * bronchospasm, * anaphylactic reactions, * malignant hyperthermia
Conditions Cystic Fibrosis, Pulmonary Fibrosis, Tub...
Phase Not Applicable
Enrollment 3500
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers. Optional CT Sub-study The standard CT scan will be compared to the low dose radiation CT scan for the 150 subjects enrolled in the sub-study to assess the variation between the two techniques. Specifically, the quantitative computer aided detection of lung CT abnormalities from LAM can be compared to assess whether low radiation dose CT exams is an alternative to conventional CT to monitor disease status. This optional sub-study will be offered to up to 100 adult subjects with lung disease and up to 50 children age 9 and older with CF. Children will not be enrolled in the optional CT sub-study unless they have had a standard CT scan for medical purposes to use in comparison. One additional low dose radiation CT scan of the chest may be done as part of this sub-study when these subjects have their next annual CT scan.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • evaluating the role of hereditary factor (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 1996-09-13
Completion: Ongoing
Eligibility
Age: 2 Years – 90 Years
Sex: ALL
Volunteers: true
Enrollment: 3500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Collaborators: Suburban Hospital
Principal Investigators:
  • Joel Moss, M.D. (PRINCIPAL_INVESTIGATOR) - National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Tatyana A Worthy, R.N.
(301) 827-1376
worthyt@mail.nih.gov
Joel Moss, M.D.
(301) 496-1597
mossj@nhlbi.nih.gov
Tatyana Worthy, B.S.
301-827-1376
worthyt@mail.nih.gov
National Institutes of Health Clinical Center
Interventions
N/A
Study Locations (2 sites)
Suburban Hospital, Bethesda, Maryland 20814 United States
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: Inclusion criteria for patients with AAT deficiency include: (1) Diagnosis of AAT with a confirmed phenotype considered in the high risk category; (2) Clinical phenotype consistent with potential genetic diseases and other genetic causes of lung diseases (3) symptoms consistent with pulmonary disease; (4) chest x-ray consistent with pulmonary disease; (5) pulmonary function tests consistent with pulmonary disease; (6) smokers, defined as individuals who are current smokers (1 pack per day for at least 2 years) and nonsmokers, defined as never-smokers or ex-smokers who have quit smoking three or more years ago; Inclusion criteria for individuals with chronic obstructive pulmonary diseases include: 1. symptoms consistent with pulmonary disease 2. chest x-ray consistent with pulmonary disease 3. pulmonary function tests consistent with pulmonary disease; 4. smokers, defined as individuals who are current smokers (1 pack per day for at least 2 years) and nonsmokers, defined as never-smokers or ex-smokers who have not smoked for three or more years. Inclusion criteria for patients with cystic fibrosis include a defined genetic mutation (i.e., any of the known variants of the CFTR gene, such as delta F508 allele) or a cystic fibrosis phenotype and clinical features consistent with this disease. Children with cystic fibrosis over eight years of age may be included. Patients with established diagnoses of sarcoidosis; mycobacterial infections; TSC (definite or possible); cystic lung diseases including genetic diseases; lymphangioleiomyomatosis or diseases associated with lymphatic disorders; history of pneumothorax; pulmonary fibrosis; asthma; histiocytosis X and diabetes mellitus will be included in this protocol. Relatives of patients may also be seen under this protocol. Children with lymphangiomatosis who are two years of age or older may be included. Participants with asthma may be enrolled at Suburban Hospital. Research volunteers in the pulmonary control group are defined as individuals with no pulmonary disease (e.g. rheumatoid arthritis without evidence of pulmonary disease). Research volunteers in the diabetes control group are defined as individuals with no history of diabetes, coronary artery disease, or pulmonary disease. Pregnant and or nursing women can be included in accordance with Federal Regulations at Subpart B of 45 CFR 46. Subjects who are pregnant and or nursing will be excluded from procedures during their pregnancy that are greater than minimal risk, until they are no longer pregnant and/or nursing. Procedures that will not be completed while the subject is pregnant and/or nursing including: PFTs, Six Minute Walk Test, thoracentesis, bronchoscopy, and measurements with imaging modalities requiring contrast or with radiation exposure such as Chest x-ray, CT scan, MRI. Allowing subjects to be included in the study may glean important information about individuals with uncommon pulmonary disease during and post pregnancy. Patients with abnormalities in ADP-ribosyltransferases, ADP-ribosyl-acceptor hydrolases, and their substrates. Children who are two years of age or older may be studied if they have a known defect in ADP-ribosylation, or if they have a family member with a defect in ADP-ribosylation and may be affected. EXCLUSION CRITERIA: Exclusion criteria for all participants include: 1. age less than 18 or greater than 90 except for NIH patients with diseases /disorders as described in this protocol (except cystic fibrosis, lymphangiomatosis or defects in ADP-ribosylation) who are 16 years of age or older, patients with cystic fibrosis who are over eight years of age, patients who are two years of age or older with lymphangiomatosis or a known defect in ADP-ribosylation, or who have a family member with a defect in ADP-ribosylation, or unless patient-specific IRB approval is obtained and; 2. inability to obtain reliable pulmonary function testing. As clarification, healthy volunteers, relatives of patients (except as noted for an ADP-ribosylation defect), and asthmatic patients from Suburban Hospital will be excluded if less than 18 or greater than 90 years of age. Exclusion criteria for participating in the bronchoscopy portion of the study are: 1. presence of any contraindication for fiberoptic bronchoscopy, with lavage and/or bronchial brushing; 2. advanced stage of a pulmonary or a systemic illness such that the risk is judged to be significant even in the absence of a specific contraindication to the procedure 3. allergy to topical anesthetic (e.g., lidocaine) 4. current or recent respiratory infection (within the last 4 weeks) 5. pregnancy or lactation 6. age less than 18 or greater than 65.
Conditions Asthma in Children
Phase NA
Enrollment 430
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The investigators propose a randomized controlled trial of Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER) vs. enhanced care (EC). TEACH-ER includes: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine (Zoom) when possible, featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. The investigators will enroll 430 children (ages 3-12 yrs) from the two dedicated pediatric EDs in our region, and follow all participants for a 12-month period. The investigators will call caregivers to complete blinded follow-up telephone surveys at 3, 6, 9, and 12 months after discharge. The investigators will assess the effectiveness of TEACH-ER in reducing the need for additional asthma-related ED visits or hospitalizations in the 1-months after enrollment. Additional outcomes of interest include asthma symptoms, medication adherence, absenteeism from work and school, quality of life, and the delivery of care consistent with national asthma care guidelines.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER) — TEACH-ER aims to provide primary care management and educational support for families managing childhood asthma throughout the transition from emergency department to home, and includes several core components: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine (when possible), featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices. We anticipate that all three telehealth visits (1 provider visit, 2 educator visits) will be completed within 2 months of enrollment.
  • Behavioral: Enhanced Care (EC) — Similar to children in the TEACH-ER group, participants in the EC group will receive a symptom assessment using NHLBI guidelines, a recommendation for appropriate preventive medications, and asthma education materials given at the time of the ED visit. After baseline and randomization, we will send the child's PCP a symptom report with guideline-based recommendations for preventive care and recommend a follow-up visit with the PCP. We will also give all providers a summary of the current national guidelines. We will provide systematic feedback to the family and child's PCP at intervals that parallel the TEACH-ER group's telemedicine assessments. This feedback will include prompting caregivers to schedule a recommended follow-up appointment with the PCP, and encouraging providers to adhere to the NHLBI guidelines. While participants will not be blinded to their group allocation, they will be told that they are randomly assigned to two different ways of approaching asthma management.

Primary Outcomes

  • Number of asthma-related hospitalizations and emergency department visits after discharge (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2028-06-30
Eligibility
Age: 3 Years – 12 Years
Sex: ALL
Volunteers: false
Enrollment: 430 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Rochester
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Sean Frey, MD, MPH
585-275-1920
sean_frey@urmc.rochester.edu
University of Rochester Medical Center
Jill Halterman, MD, MPH
585-275-5798
jill_halterman@urmc.rochester.edu
University of Rochester Medical Center
Interventions
  • Behavioral: Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER) — TEACH-ER aims to provide primary care management and educational support for families managing childhood asthma throughout the transition from emergency department to home, and includes several core components: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine (when possible), featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices. We anticipate that all three telehealth visits (1 provider visit, 2 educator visits) will be completed within 2 months of enrollment.
  • Behavioral: Enhanced Care (EC) — Similar to children in the TEACH-ER group, participants in the EC group will receive a symptom assessment using NHLBI guidelines, a recommendation for appropriate preventive medications, and asthma education materials given at the time of the ED visit. After baseline and randomization, we will send the child's PCP a symptom report with guideline-based recommendations for preventive care and recommend a follow-up visit with the PCP. We will also give all providers a summary of the current national guidelines. We will provide systematic feedback to the family and child's PCP at intervals that parallel the TEACH-ER group's telemedicine assessments. This feedback will include prompting caregivers to schedule a recommended follow-up appointment with the PCP, and encouraging providers to adhere to the NHLBI guidelines. While participants will not be blinded to their group allocation, they will be told that they are randomly assigned to two different ways of approaching asthma management.
Study Locations (1 sites)
University of Rochester Medical Center, Rochester, New York 14642 United States
Eligibility Criteria
Inclusion Criteria (all criteria must be met): * Physician diagnosis of asthma, based on review of medical records and/or caregiver report. * Current emergency visit for an acute asthma exacerbation, requiring treatment with rescue medication. * Persistent asthma or poor asthma control for which a daily controller medication is recommended by NHLBI guidelines, defined as any 1 of the following: 1. \>2 days/wk with asthma symptoms in the past month, 2. \>2 days/wk with rescue medication use in the past month, 3. \>2 days/month with nighttime symptoms in the past month (vs. 1-2 nights per month if 3-4 years old), or 4. ≥1 other episode of asthma during the past year that required systemic corticosteroids (vs. during the past 6 months if 3-4 years old). * Child age between ≥3 and ≤12 years. * Child and caregiver live in the greater Rochester, NY metropolitan area (Monroe, Wayne, Ontario, Livingston, Genesee, and Orleans Counties) * Emergency severity index triage scores of 2-5 (total range 1-5; scores of 1 indicate the highest acuity and likelihood of hospitalization). Exclusion Criteria: * An inability to speak and understand English. Parents (and children) with low literacy / health-literacy skills will be eligible, as survey instruments will be administered verbally and educational materials will be designed for low-literacy populations. * No access to a working phone for follow-up surveys (either at the subject's home or an easily accessible location). If a subject does not have access to an appropriate device for Zoom visits at home, we will provide a device with required data plan. * Other significant medical conditions, including cystic fibrosis, congenital heart disease, or other chronic lung disease, that could interfere with the assessment of asthma-related measures. * Children in foster care or other situations in which consent cannot be obtained from a legal guardian.
Conditions Allergic Rhinitis Due to House Dust Mite
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is a Study to Understand How to Better Match Allergy Shots to a Child's Unique Mite Allergy Profile 1. Why is this study being done? For many children, tiny house dust mites are a major cause of persistent allergies, leading to uncomfortable symptoms like a stuffy nose, sneezing, and even asthma. A common long-term treatment is allergy shots, also known as allergen immunotherapy (AIT). These shots work like a vaccine, slowly training the body's immune system to stop overreacting to mites. However, not every child responds to this treatment in the same way. The investigators now know that children can be allergic to different parts of the dust mite. While most treatments focus on the most common parts (called "major allergens"), some children are allergic to other, less common parts (called "intermediate or minor allergens"). The EXPLORER study wants to find out if a child's unique allergy profile-meaning which specific mite proteins they are allergic to-affects how well they respond to allergy shots. Our goal is to move away from a "one-size-fits-all" approach and toward more personalized care for children with dust mite allergies. 2. Who is this study for? The investigators are looking for children and teenagers (ages 5 to 18) in China who have a confirmed dust mite allergy and are planning to start allergy shots. 3. What will happen during the study? This is an "observational" study, which means the investigators will simply observe and track the progress of children who are already receiving a standard, approved allergy shot treatment as part of their regular medical care. The investigators won't be testing a new drug. Here's what participation involves: A Detailed Allergy Test: At the beginning, participants will have a special blood test. This test will look for allergies to nine different specific parts of the dust mite, giving us a very detailed map of their allergy. Grouping: Based on the results of this test, participants will be placed into different groups according to their specific allergy patterns. Tracking Progress: The investigators will follow their treatment journey for three years. The investigators will collect information at regular check-ups (at 0, 3, 6, 12, 24, and 36 months) on: How well their symptoms are controlled. How much allergy medication they need. Their overall quality of life. Any side effects from the shots. Annual Blood Tests: Once a year, the investigators will repeat the detailed blood test to see how their immune system is changing in response to the treatment. 4. What do the investigators hope to learn? The investigators have a main theory, or hypothesis: Children who are allergic to many different parts of the dust mite (including the minor ones) will show greater improvement from the allergy shots, compared to children who are only allergic to the most common parts. By studying a large group of 1,000 children, the investigators hope to provide clear evidence that can help…

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • The Changes of CSMS (evaluated at months 3, 6, 12, 24, and 36)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-01
Completion: 2028-11-01
Eligibility
Age: 5 Years – 18 Years
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Children's Hospital of Zhejiang University School of Medicine
Principal Investigators:
  • Lanfang Tang, PhD (STUDY_DIRECTOR) - The Children's Hospital of Zhejiang University School of Medicine
Contact Information
Study Contact:
Yujia Xiao, PhD
86+13397813805
6195007@zju.edu.cn
Yujia Xiao, PhD
86+13397813805
hero.xiaoxiao@icloud.com
The Children's Hospital of Zhejiang University School of Medicine
Interventions
N/A
Study Locations (1 sites)
The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 China
Eligibility Criteria
Inclusion Criteria: -(1) Age: 5 years ≤ age \< 18 years; (2) 1) Allergic rhinitis caused by Dermatophagoides pteronyssinus and/or Dermatophagoides farinae; 2) Or serum specific IgE ≥ 0.70 (kU/L) (for D. pteronyssinus and/or D. farinae); (3) Children meeting criteria (2) must undergo allergen component testing; (4) If accompanied by bronchial asthma, asthma must be diagnosed according to the Guidelines for the Diagnosis and Prevention of Childhood Bronchial Asthma (2025 edition) and the patient's asthma symptoms must be confirmed as well-controlled. (5) Receiving treatment with dual-mite (Dermatophagoides pteronyssinus and farinae) subcutaneous immunotherapy (SCIT). Exclusion Criteria: * (1) Participants and/or their parents/legal guardians are judged by the investigator to be unable to fully understand the study requirements, or to adhere to long-term treatment and identify adverse reactions (including but not limited to conditions such as cognitive impairment or mental illness); (2) Children with severe or uncontrolled asthma (FEV1 \< 70% of predicted value) or with irreversible airflow obstruction; (3) Children using beta-blockers or angiotensin-converting enzyme inhibitors (ACEI); (4) Children with severe autoimmune diseases or immunodeficiencies, including AIDS, inflammatory bowel disease, etc., as well as those currently using immunosuppressants; (5) Children with severe cardiovascular diseases or malignant tumors; (6) Children with incomplete clinical data.
Conditions Acute Otitis Media (AOM), Strep Pharyngi...
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the diagnostic performance, usability, and clinical utility of the Medentum Diagnostik platform, a multisensor device with integrated software and artificial intelligence, in pediatric patients with asthma and ENT conditions. Participants will be assigned to either home-based use of the Diagnostik platform with telehealth-supported clinician evaluation or standard in-person care. The primary objective is to assess agreement between AI-generated diagnoses and clinician diagnoses obtained during study encounters, including telehealth evaluations in the Diagnostik arm and in-person evaluations in the standard-of-care arm. Secondary objectives include evaluating agreement between AI-generated diagnoses and independent research team diagnoses, as well as assessing usability, patient and caregiver satisfaction, healthcare utilization, and clinical outcomes such as asthma control and symptom resolution. This study will also evaluate differences in healthcare utilization, including in-person visits, emergency care use, and time to diagnosis and treatment, between study groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of AOM and strep pharyngitis — Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of AOM and strep pharyngitis
  • Device: Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of wheeze/asthma exacerbation — Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of wheeze/asthma exacerbation
  • Other: Routine Asthma Management (in-person and telehealth visits)- Control Group — * Patients randomized to the control group will receive standard care through routine in-office visits or telehealth visits. * Patients in the control group will visit the clinic whenever they experience symptoms related to their asthma condition or any other non-respiratory, non-ENT medical condition. * Telehealth visits will be offered as per routine and determined by the medical provider. * Asthma patients will undergo a physical exam, and other lab studies (e.g. Covid, strep tests) as determined by the provider to aid in diagnosis and treatment plan. The medical provider will make a diagnosis based on these routine in-office or telehealth assessments. * Control group patients will have routine well-care in-office follow-ups at a frequency as determined by their routine provider.
  • Other: Routine ENT Management (in-person and telehealth visits)- Control Group — * Patients randomized to the control group will receive standard care through routine in-office visits or telehealth visits. * Patients in the control group will visit the clinic whenever they experience symptoms related to their ENT condition or any other non-respiratory, non-ENT medical condition. * Telehealth visits will be offered as per routine and determined by the medical provider. * ENT patients will undergo a physical exam, and other lab studies (e.g. Covid, strep tests) as determined by the provider to aid in diagnosis and treatment plan. The medical provider will make a diagnosis based on these routine in-office or telehealth assessments. * Control group patients will have routine well-care in-office follow-ups at a frequency as determined by their routine provider.

Primary Outcomes

  • Diagnostic concordance between AI and physician/clinician (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2026-12-01
Eligibility
Age: 3 Years – 17 Years
Sex: ALL
Volunteers: true
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medentum Innovations
Collaborators: University of Arizona, National Institutes of Health (NIH), El Rio Community Health Center
Contact Information
Study Contact:
Starla Kiser, Medical Degree
276-212-1863
starla@medentum.com
Erin Dougherty, Masters Degree
520-670-3909
ErinD@elrio.org
El Rio Health System
Interventions
  • Device: Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of AOM and strep pharyngitis — Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of AOM and strep pharyngitis
  • Device: Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of wheeze/asthma exacerbation — Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of wheeze/asthma exacerbation
  • Other: Routine Asthma Management (in-person and telehealth visits)- Control Group — * Patients randomized to the control group will receive standard care through routine in-office visits or telehealth visits. * Patients in the control group will visit the clinic whenever they experience symptoms related to their asthma condition or any other non-respiratory, non-ENT medical condition. * Telehealth visits will be offered as per routine and determined by the medical provider. * Asthma patients will undergo a physical exam, and other lab studies (e.g. Covid, strep tests) as determined by the provider to aid in diagnosis and treatment plan. The medical provider will make a diagnosis based on these routine in-office or telehealth assessments. * Control group patients will have routine well-care in-office follow-ups at a frequency as determined by their routine provider.
  • Other: Routine ENT Management (in-person and telehealth visits)- Control Group — * Patients randomized to the control group will receive standard care through routine in-office visits or telehealth visits. * Patients in the control group will visit the clinic whenever they experience symptoms related to their ENT condition or any other non-respiratory, non-ENT medical condition. * Telehealth visits will be offered as per routine and determined by the medical provider. * ENT patients will undergo a physical exam, and other lab studies (e.g. Covid, strep tests) as determined by the provider to aid in diagnosis and treatment plan. The medical provider will make a diagnosis based on these routine in-office or telehealth assessments. * Control group patients will have routine well-care in-office follow-ups at a frequency as determined by their routine provider.
Study Locations (1 sites)
El Rio Health System, Tuscon, Arizona 85745 United States
Eligibility Criteria
Inclusion Criteria: * Age: Patients between the ages of 4 and 17 years (asthma) and 3-17 years (ENT) * Diagnosis: o Asthma patients: Diagnosed with mild-to-moderate and severe persistent asthma according to Global Initiative for Asthma (GINA) guidelines, with a history of symptoms or exacerbations requiring medical intervention (prior prednisone course and/or albuterol for \>24 hours in context of acute wheezing episode) in the past 12 months. ENT patients: Diagnosed with common ENT conditions such as acute otitis media (AOM) or strep pharyngitis in the prior year. Diagnosis must be based on established clinical guidelines. * Technology access: Must have access to a smartphone, tablet, or other device capable of running the Medentum Diagnostik platform app and access to Wifi or cellular service. * Care access: Must be receiving routine care from University of Arizona or associated clinics in Arizona and have active health insurance * Consent: Must have parental or guardian consent for participation, as well as child assent when appropriate.(all children ≥7 yrs) Exclusion Criteria: * Other medical conditions: Patients with additional chronic lung diseases (such as cystic fibrosis) requiring complex specialist care will be excluded. cerebral palsy, neurodevelopmental conditions, congenital heart disease. Patients with complex chronic conditions or chronic ENT conditions requiring complex specialist care will be excluded. * Recent surgical/complex ENT medical history: Patients who have had tympanostomy tubes or tonsillectomy/adenoidectomy, patients with chronic ENT conditions including chronic suppurative or serous otitis media * Recent medical history: Patients who have experienced severe asthma exacerbations requiring hospitalization or intensive treatment in the past 4 weeks * Comorbidities: Patients with speech delays, hearing impairments, or cognitive impairments that may affect their ability to use the Diagnostik platform accurately will be excluded. * Non-compliance risk: Patients or families that are unable to follow study instructions, comply with follow-up visits, or properly use the Medentum platform will be excluded.
Conditions Microbial Colonization, Atopic Dermatiti...
Phase NA
Enrollment 320
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities that is associated with altered commensal microbiota and a rising burden of immunological disorders among urban children. The investigators will estimate how rewilding of kindergarten yards affects commensal microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol levels, cognitive skills and plasma cytokine levels of children. Our specific aims are: To assess if rewilding diversifies health-associated skin, saliva and gut microbiota and reduces infectious diseases and atopic or allergic symptoms. Assess whether the rewilding has positive effects on cognitive skills. Assess whether the rewilding changes cortisol and plasma cytokine levels. The investigators will recruit altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study (Task 2), from which 120 study subjects will be analyzed more detailed using microbiological and blood samples (Task 1).

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Biodiversity — In rewilding kindergartens, the yards are modified with biological elements, i.e., vegetation and plantation will be added to the yards.
  • Other: Playground equipment — Playground equipment that increase the physical activity of children will be added to the kindergarten yards.

Primary Outcomes

  • Skin Gammaproteobacteria (Baseline, 3 month, 1 year, 2 year, 3 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-15
Completion: 2027-08-30
Eligibility
Age: 1 Year – 5 Years
Sex: ALL
Volunteers: true
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Natural Resources Institute Finland
Collaborators: Tampere University
Principal Investigators:
  • Aki Sinkkonen (PRINCIPAL_INVESTIGATOR) - Natural Resources Institute Finland
Contact Information
Study Contact:
Sanna Hurtola
+358295322500
sanna.hurtola@luke.fi
Marja Roslund
+358295322256
marja.roslund@luke.fi
Natural Resources Institute Finland
Laura Kummola, Phd
laura.kummola@tuni.fi
Tampere University
Interventions
  • Other: Biodiversity — In rewilding kindergartens, the yards are modified with biological elements, i.e., vegetation and plantation will be added to the yards.
  • Other: Playground equipment — Playground equipment that increase the physical activity of children will be added to the kindergarten yards.
Study Locations (2 sites)
Natural Resources Institute Finland, Helsinki, Uusimaa 00970 Finland
Tampere University, Tampere, Finland
Eligibility Criteria
Inclusion Criteria: * Attendance in kindergarten Exclusion Criteria: * Use of antibiotics in the year before sampling